AbbVie CEO Leads US$1.4bn Manufacturing Expansion
AbbVie is investing £1.1bn (US$1.4bn) in a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, marking the company’s largest capital investment to date. The decision represents a significant strategic move by the pharmaceutical giant to expand its US manufacturing footprint into a new region.
The campus will integrate advanced manufacturing and laboratory technologies as well as AI to support the production of immunology, neuroscience and oncology medicines. AbbVie expects the facility to create 734 jobs, including engineers, scientists, manufacturing operators and laboratory technicians.
The first phase of construction will include small volume parenteral drug product manufacturing facilities, next-generation laboratories, a warehouse, administrative offices and employee wellness facilities. Small volume parenterals are sterile injectable pharmaceutical products with volumes typically less than 100ml, including vials, prefilled cartridges and prefilled syringes containing medicines for injection or infusion.
